ZEE5 Global, the world's largest streaming platform for South Asian content, has announced the world digital premiere of the highly acclaimed Marathi film Vaalvi.
After bringing forth blockbuster Marathi films like Pandu, Zombivali, Har Har Mahadev, and Timepass 3, ZEE5 Global is set to premiere Vaalvi on 24th February.
Directed by Paresh Mokashi, the film stars Swwapnil Joshi, Subodh Bhave, Anita Date-Kelkar, and Shivani Surve in leading roles.
Produced by Zee Studios and Madhugandha Kulkarni, Vaalvi successfully ran at the box office.
The film starts with Avni (Anita Date-Kelkar) and Aniket (Swapnil Joshi), a couple, deciding to kill themselves simultaneously. They are convinced that there is no way out of their financial problems and that suicide is the best solution. However, as it turns out, this is not a suicide mission, but an attempt to murder, and the masterminds behind this are Aniket and his girlfriend Devika (Shivani Surve) in the hope of getting rid of Aniket’s nagging wife. There is also a mysterious man (Subodh Bhave) with a hidden ulterior motive. What happens further on judgment day is what the film is about.
With an IMDb rating of 8.8, Vaalvi is amongst the highest-rated Marathi films. It was appreciated by critics and viewers alike for its unique plot, unexpected twists and turns, and strong performances by the actors. With its World Digital Premiere on ZEE5 Global on 24th February, the film will be available to viewers across 190+ countries.
Archana Anand, Chief Business Officer, ZEE5 Global, said, “At ZEE5 Global, we have always endeavoured to bring a colourful linguistic diversity to global viewers through our vast content library. With the release of the Marathi thriller comedy, Vaalvi, we take a step further towards taking Marathi stories to the world. The movie brings to viewers a pacy, funny, and engaging watch that is sure to keep them on the edge of their seats.”
Director Paresh Mokashi said, “Vaalvi is a quirky dark thriller comedy and a genre which is not extensively explored in Marathi cinema; hence, I am overwhelmed with the response from critics and fans alike as they have liked and appreciated our unusual attempt. Now with Vaalvi’s World Digital Premiere on ZEE5 Global, I am excited about the film’s second innings. For those who haven’t watched the film already, I can promise that Vaalvi will take them by surprise and keep them entertained and intrigued through the constant twists and turns”.
Actor Swwapnil Joshi said, “Vaalvi was an experimental role for me as it is unlike anything I have portrayed before, and I am thrilled with the response. My director (Paresh) helped me broaden my horizon as an actor and pushed me out of my comfort zone, for which I am grateful. I am also grateful to the viewers for appreciating this film and giving it their love. Now with Vaalvi’s World Digital Premiere on ZEE5 Global, I am excited for the film to reach a wider audience base worldwide. I insist that people sample this film as it is a deliciously written, twisted black-comedy and a satirical take on a crime of passion”.
Watch Vaalvi from 24th February 2023 exclusively on ZEE5 Global!
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.